Human transcript validation initiative

• Processo: 00/12491-9
• Modalidade de apoio: Auxílio à Pesquisa - Programa GENOMA
• Data de Início da vigência: 01 de dezembro de 2000
• Data de Término da vigência: 31 de março de 2003
• Área do conhecimento: Ciências Biológicas - Bioquímica - Biologia Molecular
• Pesquisador responsável: Eugenia Costanzi-Strauss
• Beneficiário: Eugenia Costanzi-Strauss
• Instituição Sede: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brasil
• Assunto(s): Oncogenes Análise de sequência de DNA Neoplasias DNA recombinante Genoma Humano do Câncer
• Palavra(s)-Chave do Pesquisador: Cancer Genome | Gene Discovery | Oncogenes | Recombinant Dna | Sequence Analysis

Resumo

The Cancer Genome Project has generated previously uncharacterized sequences which may represent genes important in the formation of human cancer. The complete cDNA of these potential genes must be obtained and defined. This is a critical first step in the biochemical study of the function of these novel cancer genes. The Gene Transfer and Cell Cycle Manipulation Laboratory, ICB, USP, has extensive experience in recombinant DNA techniques that will be necessary for the successful execution of the Validation Initiative. Our group builds retroviral gene transfer vehicles using molecular cloning protocols, such as PCR amplification of DNA/RNA fragments, ligation of these fragments in plasmid vectors, and sequence and functional analysis of the novel constructs. Since our group works with tumor suppressor genes, we are adept at handling potentially cytotoxic and cytostatic cDNA's. In addition, our experience with mutants of p53 has given us insight in the study of growth promoting genes. Drs. Strauss and Costanzi-Strauss have successfully collaborated and published in the area of cell cycle control, gene regulation and gene transfer. These studies have examined important genes (p16, p21, p53, Rb) in the formation/prevention of tumors at the DNA, RNA and protein levels. Currently, we study the molecular profile of tumors, the in vivo function of tumor suppressor genes and we are developing novel retroviral vectors in order to improve cancer gene therapy strategies. (AU)